CIO Bulletin

Science 37 – Revolutionizing clinical research through extensive decentralization strategies to enhance home-based trials and patient-centric innovations

The decentralization of clinical trials has emerged as a significant and evolving topic, fueled by technological advancements. This shift in approach is crucial for prioritizing patient needs throughout the clinical trial journey and influencing the development of processes and policies. Among the various strategies to achieve decentralization, the adoption of home-based trials is gaining momentum, driven by successful implementations and ongoing technological progress.

A key player in transforming the promise of virtual trials into reality is Science 37. The company engages with patients in the comfort of their homes, providing access to individuals who may not be reachable through traditional site-based models. Science 37 has demonstrated faster enrollment, higher patient retention rates, and a more diverse participant population. Distinguished as the company with the most extensive experience in conducting decentralized, interventional trials, Science 37 employs an in-house network of telemedicine investigators and home-health nurses. These professionals are supported by the industry's most comprehensive and fully integrated decentralized clinical trial platform, contributing to the evolution of patient-centric and accessible clinical research.

Unlocking the Flexibility of Hybrid Clinical Trials: A Global, Scalable Platform

In the realm of clinical trials, Science 37 introduces a revolutionary approach, providing a spectrum of hybrid clinical trials that accommodate both traditional and non-traditional elements. This innovative platform, which is global, scalable, and configurable, serves as a comprehensive end-to-end clinical trial Software as a Service (SaaS) platform. It empowers decentralized clinical trials by seamlessly incorporating technologies such as Telemedicine, eConsent, eCOA/ePRO, and eSource, supporting sponsors and Contract Research Organizations (CROs) at every stage of the clinical trial process. Navigating Agile (hybrid) Clinical Trials is made seamless through centralized networks, allowing patients to be recruited, enrolled, and seen from any location. Science 37's expansive networks include patient communities, mobile nursing, remote coordinators, community providers, and data and devices.

Metasite^™: Elevating Diversity in Clinical Trials Through Virtual Innovation

To accelerate patient recruitment, enrollment, and retention while enhancing diversity, Science 37 introduces Metasite^™, powered by the Science 37 Operating System^™. This virtual site eliminates geographical barriers, providing access to patients and providers regardless of their location. By complementing traditional brick-and-mortar site strategies, Metasite^™ extends the reach of clinical trials, expediting recruitment, advancing retention, improving data quality, and enhancing the overall patient experience. Metasite^™ allows any patient and any provider to access clinical trials, thereby accelerating enrollment, improving data quality, and delivering a more diverse participant population – ultimately facilitating the market entry of breakthrough treatments. Patients can now be seen at both traditional sites and in the comfort of their homes, thanks to broadly-licensed telemedicine physicians, in-house mobile healthcare providers, and research coordinators.

Operating System^™: Revolutionizing Recruitment for Breakthrough Treatments

The Science 37 Operating System^™ emerges as a game-changer in clinical trial recruitment. Its capability to recruit any patient or provider contributes to accelerated recruitment, improved data quality, and the delivery of a more representative participant population, ultimately expediting the journey of breakthrough treatments to market. This operating system facilitates the implementation of Agile Clinical Trials^™ tailored to the unique needs of each study. Patients have the flexibility to be seen either in the comfort of their homes or by a local provider, fostering a patient-centric approach. Quality providers seamlessly collaborate with Science 37's technology platform to operationalize, conduct, and support increasingly complex hybrid and decentralized clinical trial designs, both at-home and on-site within local communities. The Science 37 Operating System^™ ensures that the acceleration of trials with multi-channel patient access, including Science 37’s registry of 500k+ patients, attracting, enrolling, and retaining participants beyond traditional sites, thus delivering a real-world representation in clinical trials.

About | David Coman

David Coman is the Chief Executive Officer of Science 37, which makes it easier for people to participate in clinical research by connecting patients with doctors and nurses through telemedicine visits and home health screenings, then managing trial logistics from an integrated, comprehensive platform.

David came to Science 37 from ERT, where he led its data and analytics business after serving as the company’s chief strategy officer. As the leader of ERT’s data and analytics business, David reimagined the way the pharmaceutical industry looks at performance and risk management for clinical trials while more than doubling the company’s bookings from analytics over a two-year period. In his strategy role, David spearheaded the acquisition of four companies in a 12-month period, generating more than $1 billion in enterprise value, while repositioning ERT as the market leader in clinical trial data generation.

David joined ERT from Quintiles (now IQVIA), where as chief marketing officer and founder of its Digital Patient business, he helped lead the company’s growth from $2.7 billion in 2007 to $4.3 billion in 2015. It was here that David pioneered some of the industry’s first decentralized clinical trials while also driving significant growth and enterprise value.